Skip to main content
. 2012 Oct 1;13(12):1175–1184. doi: 10.4161/cbt.21347

graphic file with name cbt-13-1175-g8.jpg

Figure 8. Cotreatment with cisplatin combined TRAIL-MSCs reduced vessel density in HCC. Tumors from control group, cisplatin group or TRAIL-MSCs group showed intense and diffuse CD34 immunoreactivity, whereas MVD from cotreatment group was significantly lower (A). Representative tumor sections stained with an anti-CD34 antibody are shown (B, ×200). Asterisk indicates p < 0.05, co-treatment group vs. control and monoagent groups (n = 6).